Maynard Um
-
-
-
-
-
-
-
Silexion Therapeutics (SLXN) Misses Q3 EPS by 288c
-
-
-
-
-
-
-
Silexion Therapeutics (SLXN) Reports Preclinical Results for SIL204
-
-
-
-
-
-
-
Sielox, Inc. (SLXN) Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
-
-
-
-
404,875 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

